0
  • Notifications
  • No notifications yet

  • View All Notifications
ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Health Canada Approves New Indication For Mercks Prevymis
News Feed
course image
  • 23 Apr 2024
  • Admin
  • News Article

Health Canada Approves New Indication for Merck’s Prevymis

Health Canada approves new indication for Merck’s Prevymis for prevention of CMV disease in high-risk adult kidney transplant recipients

Overview

Merck, known as MSD outside of the United States and Canada, announced that Health Canada has approved a new indication for Prevymis (letermovir)  for the prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]).

Words from Merck Canada

  • “We are pleased that Prevymis has received Health Canada approval to help prevent CMV disease in high-risk adult kidney transplant patients.” said Philippe Houle, executive director of infectious diseases and specialty medicines at Merck Canada. 
  • “Our focus remains solely on providing innovative medicines to address the unmet needs of all Canadians.”

Trial Behind Approval

  • Health Canada’s approval of Prevymis for CMV disease prophylaxis in adult kidney transplant recipients was supported by a phase 3, randomized, multicenter, double-blind, active comparator-controlled non-inferiority trial (P002, NCT03443869) in 589 adult kidney transplant recipients at high risk (CMV D+/R-). 
  • Participants were randomized (1:1) to receive either Prevymis concomitantly with acyclovir (n=292), or valganciclovir concomitantly with a placebo to acyclovir (n=297). 
  • Study drug was initiated between Day 0 and Day 7 post-kidney transplant and continued through Week 28 (~200 days) post-transplant. 
  • Study drug was administered either orally or IV; the dose of Prevymis was the same regardless of the route of administration.

About Merck

  • Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: The company use the power of leading-edge science to save and improve lives around the world. 
  • For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form